Abstract
The high local and distant recurrence rate after thoracic radiation deserves the development of new strategies to improve the outcome of patients with Stage III non-small cell lung cancer (NSCLC). The addition of chemotherapy (CT) to radiotherapy has seen a decrease in the metastasis rate in some controlled studies with a favorable impact on overall survival. However, the optimal schedule of both modalities remains to be defined. The persistent poor local control in these studies underestimates the real impact of chemotherapy on patients' outcome and calls for new investigational approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
